source
- Moderna and Merck report late-stage success for personalized mRNA cancer vaccineModerna and Merck announced that their personalized cancer vaccine achieved its primary goals in a late-stage clinical trial, sparking enthusiasm across the biotech community. The experimental the…
- Alnylam’s heart drug outlook dimmed as rival eplontersen fails at ESC CongressThe European Society of Cardiology Congress in Munich is a focal point for Alnylam Pharmaceuticals as it seeks clarity on the future of its two ATTR-CM programs. Data presented by AstraZeneca and…